Breaking New Ground: Annovis Bio Secures $21M to Pioneer Neurodegeneration Therapies

In an exciting development for the neuroscience community, Annovis Bio, Inc.

has successfully raised $21,000,000 to further advance its groundbreaking mission of combating chronic and acute neurodegeneration.

At Annovis Bio, we are pioneering a novel approach to fighting some of the most challenging neurologic disorders of our time, including Alzheimer’s, Parkinson’s, and other conditions such as traumatic brain injury, stroke, Down Syndrome, Huntington disease, and various mental illnesses.

The infusion of capital is set to significantly bolster our innovative pipeline, particularly our lead compound, buntanetap—a once-daily, orally administered, brain-penetrant inhibitor of neurotoxic proteins.

Having demonstrated its promising biological activity in 19 animal studies at prestigious institutions including the Karolinska Institute, Columbia University, and Harvard University, and validated through seven clinical studies involving over 1,000 participants, buntanetap continues to show nurturing potential by normalizing levels of neurotoxic proteins like APP, tau, and aSYN.

The recent funding will accelerate the submission of our latest data to the FDA and support the planning and execution of two pivotal Phase 3 studies aimed at confirming effectiveness in Alzheimer’s and Parkinson’s disease populations.

We believe that buntanetap may be the first intervention to target the underlying mechanisms of neurodegeneration, offering a beacon of hope to millions affected worldwide.

This milestone not only underscores the confidence that investors have in the promise of our science but also strengthens our commitment to revolutionize treatment paradigms for debilitating neurodegenerative diseases that continue to challenge the aging population globally.